NEWEST TO THE MARKET (EMA Drug Approvals)

 

  • Pazenir (paclitaxel) – to treat adults patients with metastatic breast cancer and non-small cell lung cancer.

Approval Date: 06 May 2019

—————————————————————————————————————————————————————————————————————————————

  • Zirabev (bevacizumab) – To treat adult patients with cancer of the colon, breast cancer that has spread to other parts of the body, a lung cancer called non-small cell lung cancer, cancer of the kidney, cancer of the cervix.

Approval Date: 16 Apr 2019

—————————————————————————————————————————————————————————————————————————————

  • Vizimpro (dacomitinib) – to treat adults patients with non small cell lung cancer (NSCLC) when the disease is advanced or has spread.

Approval Date: 02 Apr 2019

—————————————————————————————————————————————————————————————————————————————

  • Febuxostat Krka (febuxostat)  –  to treat adults patients with long-term hyperuricaemia (high levels of uric acid or ‘urate’ in the blood)

Approval Date: 28 Mar 2019

—————————————————————————————————————————————————————————————————————————————

  • Erleada (apalutamide) – to treat men with cancer of the prostate (a gland of the male reproductive system).

Approval Date: 14 Jan 2019